Gábor Somlyai

Gábor Somlyai is a prominent Hungarian molecular biologist known for his groundbreaking research on deuterium and its effects on cancer treatment. He recognized the biological significance of deuterium as early as 1990 and founded HYD LLC, a company dedicated to developing cancer therapies based on deuterium reduction. His work has led to significant advancements in oncology, including a recent study demonstrating that incorporating deuterium-depleted water (DDW) into traditional cancer treatments can drastically improve patient survival rates. Somlyai's research aligns with the principles of precision medicine, offering personalized treatment solutions based on individual biological characteristics.